Drug Profile
Alpha-v Beta-x inhibitor
Latest Information Update: 06 Aug 2013
Price :
$50
*
At a glance
- Originator Pharmacia Corporation
- Class Antineoplastics
- Mechanism of Action Angiogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 31 May 2003 Discontinued for Cancer in USA (unspecified route)
- 31 May 2002 No development reported for Cancer in USA (unspecified route)
- 05 Apr 2000 Monsanto has merged with Pharmacia & Upjohn to form Pharmacia Corporation